肝细胞癌(hepatocellular carcinoma,HCC)是临床常见的恶性肿瘤,在全球癌症发病率中居第5位,病死率居第3位[1]。近年来虽然随着手术技术及射频消融等治疗手段的不断发展,越来越多的患者获得了根治性治疗,但这部分患者占初治患者比例依然不够理想,只有30%左右,而且患者根治性治疗后复发转移率依然居高不下。对于丧失根治性治疗机会或者复发转移的患者,放化疗等传统治疗方法效果 Hepatocellular carcinoma (HCC) is a common malignant tumor in the world, occupying the 5th place in the global incidence of cancer and the third leading cause of death [1]. In recent years, although with the continuous development of surgical techniques and radiofrequency ablation and other treatment methods, more and more patients have obtained radical treatment, but this part of patients accounted for the proportion of newly diagnosed patients is still not ideal, only about 30%, and patients with radical Recurrence and metastasis rate after sexual treatment remains high. For the loss of radical treatment or recurrence and metastasis of patients with radiotherapy and chemotherapy and other traditional methods of treatment effect